Clinical Trials Browser

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms by Site, Rectal Diseases, Colorectal Neoplasms

NCT02297438 2026-05-14

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Phase 3 Completed

340 enrolled 33 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02514278 2026-05-14

GRECCAR12

Phase 3 Completed

218 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03570892 2026-05-14

BELINDA

Phase 3 Completed

330 enrolled 10 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04246177 2026-05-14

LEAP-012

Phase 3 Completed

479 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT04756037 2026-05-13

SERENE

Phase 3 Completed

1,164 enrolled 16 charts

Endometriosis, Leiomyoma

NCT05153239 2026-05-13

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Phase 3 Completed

705 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03891914 2026-05-12

MYELOCHOL

Phase 3 Completed

20 enrolled

Plasma cell

Multiple Myeloma

NCT03607539 2026-05-11

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Phase 3 Completed

397 enrolled 15 charts

Thoracic

Lung Neoplasms

NCT03274492 2026-05-08

POLARIX

Phase 3 Completed

1,000 enrolled 1 FDA

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04835142 2026-05-08

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Phase 3 Completed

688 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Phase 3 Completed

343 enrolled

Genitourinary

Carcinoma, Renal Cell, Disease Progression

NCT02973386 2026-05-07

Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

Phase 3 Completed

294 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03979014 2026-05-06

NOVEL

Phase 3 Completed

1,099 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasms

NCT03794388 2026-05-05

CAPTRANE

Phase 3 Completed

140 enrolled 6 charts

Breast

Breast Cancer Patient

NCT04199104 2026-05-05

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03740165 2026-05-04

KEYLYNK-001

Phase 3 Completed

1,367 enrolled 29 charts

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Clinical Trials

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

ADAPT NXT

SACHI

FORTITUDE-101

Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer

MK-4280A-007

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

CRANIOEXE

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

DUBLIN-3

Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

MEN-301

Viale-a

ULTIMO

GRECCAR 5

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

GRECCAR12

BELINDA

LEAP-012

SERENE

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

MYELOCHOL

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

POLARIX

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

NOVEL

CAPTRANE

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

KEYLYNK-001